Results

Search Results for:

Imaginostics Shines at the Hello Tomorrow Global Summit 2024: Revolutionizing Diagnostic Imaging with QUTE-CE MRI

March 2024 – Valerie Gharagouzloo, co-Founder at Imaginostics, is set to present at the esteemed Hello Tomorrow Global Summit in Paris, France, on March 21st-22nd, showcasing the groundbreaking QUTE-CE MRI technology that is poised to transform diagnostic imaging.

Imaginostics, a finalist in the renowned Hello Tomorrow Global Challenge, was selected from over 4,500 applicants worldwide, a testament to the innovative approach and potential impact of their QUTE-CE MRI technology. The company, under Gharagouzloo’s guidance, specializes in non-invasive, quantitative imaging technology designed to enhance vascular structure and function analysis throughout the body, with significant implications for neurology, cardiology, and oncology.

The Hello Tomorrow Global Summit is an incubator for deep tech advancements, addressing some of the most pressing global challenges through technology and innovation. This year’s summit will not only spotlight the finalists but also serve as a convergence point for industry leaders, investors, and innovators.

“Being recognized as a finalist is a monumental achievement for us,” said Gharagouzloo. “It’s a validation of our hard work and the potential of QUTE-CE MRI to revolutionize how we approach diagnostic imaging for a myriad of diseases. We’re excited to share our technology with the global community and explore partnerships that could further our impact.”

Imaginostics stands at the forefront of the Digital Health & Medical Devices category, promising a future where precise, non-invasive imaging techniques become a cornerstone of personalized medicine. The technology’s precision and its ability to provide 10X better vascular images while eliminating toxic gadolinium contrast underscore its potential to become a game-changer in the field.

The Hello Tomorrow Global Summit offers an unparalleled platform for emerging technologies, highlighting the importance of innovation in tackling health and environmental challenges. For Imaginostics, it represents an opportunity to gain visibility, attract investment, and forge partnerships that could accelerate the adoption of QUTE-CE MRI in healthcare systems worldwide.

As the summit approaches, the Imaginostics team is gearing up for what could be a pivotal moment in the company’s journey. A win at the Hello Tomorrow challenge would not only bring substantial equity-free funding but also access to a tailored coaching program and invaluable connections within the industry.

For more information about Imaginostics and the revolutionary QUTE-CE MRI technology, visit our website or follow us on social media for live updates from the Hello Tomorrow Global Summit.

Imaginostics Joins Forces with the Prestigious Paris Saclay Cancer Cluster to Revolutionize Oncology

In a significant stride towards transforming cancer research and treatment, Imaginostics is proud to announce its inclusion in the esteemed Paris Saclay Cancer Cluster (PSCC). This collaboration marks a pivotal moment in our ongoing mission to advance the predictive, precise, and efficient treatment of cancer through innovative technologies.

Founded under the visionary guidance of French President Emmanuel Macron in June 2021, the PSCC stands at the forefront of oncology innovation. Located in the vibrant heart of the Grand Paris area, specifically in Villejuif, the PSCC fosters a unique ecosystem where researchers, clinicians, innovators, and patients converge to accelerate breakthroughs in cancer care.

Imaginostics was one of the four new organizations announced in December to benefit from the power of the PSCC ecosystem, alongside Cherry Biotech, EverImmune, and Prostperia, Imaginostics is set to benefit from an unparalleled range of resources. This includes access to experts, networks, funding, data, samples, technologies, infrastructures, training, and laboratories. Our inclusion in this dynamic biocluster is a testament to the potential of our cutting-edge oncology projects to make a profound impact on patient care.

The Paris Saclay Cancer Cluster’s comprehensive offering aligns perfectly with our commitment to developing innovative solutions that meet the urgent needs of patients battling cancer. With the PSCC’s support, Imaginostics is poised to push the boundaries of what’s possible in oncology, leveraging our expertise to contribute to a future where cancer treatment is more targeted, effective, and compassionate.

To date, the PSCC has selected and supported 31 groundbreaking oncology projects, illustrating its pivotal role in fostering industrial development and innovation in the field. Imaginostics is honored to join this vibrant community of pioneers, and we are eager to collaborate with fellow members to advance our shared goal of transforming oncology research and treatment.

For those developing innovative solutions in oncology and interested in joining this trailblazing initiative, we encourage you to learn more about the application process at the PSCC’s website.

Imaginostics’ collaboration with the Paris Saclay Cancer Cluster heralds a new chapter in our journey to revolutionize oncology. Together, we are committed to making a lasting impact on the lives of patients around the world, pushing the envelope of innovation to fight cancer with unprecedented precision and efficacy.

Stay tuned for more updates on our projects and the groundbreaking work being done at the Paris Saclay Cancer Cluster.

A Journey of Faith, Love and Science: Breakthrough Longevity Tech Company Launches New Phase of Commercialization to Accelerate Drug Development

Dr. Codi Gharagouzloo, an MRI physicist, and his wife, New York attorney Valerie Gharagouzloo, created Imaginostics to advance medical breakthroughs for uncurable diseases with their imaging biomarkers.

Imaginostics, a promising startup company founded in 2018, is bringing to market a revolutionary longevity technology for early detection of diseases decades in advance through MRIs. The company’s technology uses a new way to acquire data from existing MRI scanners and hardware, improving MRIs by 10x and enabling new physiological measurements that describe the cellular vascular environment. This represents a potential breakthrough for the early detection of many age-related diseases, and in particular Alzheimer’s disease and related dementia.

Imaginostics was founded by Dr. Codi and Valerie Gharagouzloo, a French American couple who met in Valerie’s native France in 2007, were married in 2010, and have two children. Dr. Gharagouzloo invented and developed the breakthrough quantitative imaging technology during his Ph.D. in bioengineering at Northeastern University and postdoctoral research fellowship at Harvard-affiliated Massachusetts General Hospital in Boston. Valerie inspired Codi to launch his startup to bring his extraordinary tech from bench to bedside.

“At the heart of the technology is quantum physics, where we overcome the qualitative limitations of magnetic susceptibility using ultra-short measurement times 1,000x earlier than standard MRIs. As a bonus, the tech is compatible with an iron supplement for contrast and doesn’t require toxic gadolinium,” Codi said. “From there, we can quantify microvascular density, function, and leakage.”

“Alzheimer’s disease is like a black box from the day you’re born until the day you develop symptoms,” Codi added. “We’ve known that blood vessels are abnormal, but current technologies can’t quantify it at the individual level.

“There are lots of exciting drugs in development that could not only cure Alzheimer’s but extend a healthy lifespan. We are just one piece of the puzzle: quantitative imaging biomarkers of aging for fast and high-throughput testing.”

In 2022, the company raised $1.35 million in grants, including nearly $1 million from an NIH-NIA SBIR Grant for Clinical Validation for Novel MRI Biomarkers in screening and quantification of mild cognitive impairment, boosted by an investment by the Alzheimer’s Drug Discovery Foundation of $725,000. Imaginostics is fundraising another $2.2 million to consolidate the team at Lake Nona Medical City in Orlando and launch its first phase of commercialization for accelerating drug development. The company expects first sales to pharmaceutical companies in 2024, and partners with clinical research organizations.

“We are still living in the stone age with current MRIs and there haven’t been any precision advancements for decades,” Codi said. “For the first time, Imaginostics can visualize the vasculature throughout the whole body, assay health and disease, stratify patient populations, and assess drug efficacy at the individual level.”

Imaginostics is creating the next generation of precision medicine diagnostic tools for clinicians and drug developers to transform personalized healthcare, accelerate drug development and fight aging.

“Preventive medical care is better than curative care. We want to transform lives by empowering people to take control of their own health and well-being,” Valerie said.

For more information, visit https://imaginostics.com

Careers

imaginostics

An illuminative team

Are you looking for a dynamic and fulfilling job in doing critical research for imaging diagnostics? We are actively searching for additional members to join our team

About Imaginostics

Imaginostics is a longevity and health tech startup developing imaging diagnostic biomarkers for precision medicine, with a special focus on brain health. Our magnetic resonance imaging (MRI) based technology overcomes the qualitative limitations of traditional MRI and enables us to quantify brain abnormalities.

Senior MRI Physicist: Image reconstruction

Job description:


Join a growing team developing novel quantitative vascular imaging and biomarkers for precision medicine diagnostics in cardiology, neurology, and cancer

  • Work on GE and Siemens MRI scanners, and Bruker preclinical scanners
  • Implement state-of-the-art Image reconstruction methods for 3D non-cartesian imaging
  • Robust dynamic free-breathing and cardiac imaging
  • Implementation of accurate B1+/- mapping
  • Work in a dynamic environment with collaborators at leading hospitals and academic institutions

Minimum qualifications: A doctoral degree or equivalent in one of the following majors: Physics/ Medical Physics, Biomedical Engineering, Computer Science and Engineering, or Applied Mathematics. Excellent scientific writing ability and strong oral communication skills. The ability to work effectively and collegially in a multidisciplinary team.


Salary range: $150,000 - $250,000 annually. The salary will be commensurate with experience.


Location: Orlando, FL.


Please send a resume and cover letter to info@imaginostics.com for consideration. No phone calls please.

Senior MRI Physicist: Pulse Sequence Development

Job description:


Join a growing team developing novel quantitative vascular imaging and biomarkers for precision medicine diagnostics in cardiology, neurology, and cancer

  • Work on GE and Siemens MRI scanners, and Bruker preclinical scanners
  • Implement state-of-the-art Image methods for 3D non-cartesian imaging
  • Robust dynamic free-breathing and cardiac imaging
  • Implementation of accurate B1+/- mapping
  • Work in a dynamic environment with collaborators at leading hospitals and academic institutions

Minimum qualifications: A doctoral degree or equivalent in one of the following majors: Physics/ Medical Physics, Biomedical Engineering, Computer Science and Engineering, or Applied Mathematics. Excellent scientific writing ability and strong oral communication skills. The ability to work effectively and collegially in a multidisciplinary team.


Salary range: $150,000 - $250,000 annually. The salary will be commensurate with experience.


Location: Orlando, FL.


Please send a resume and cover letter to info@imaginostics.com for consideration. No phone calls please.

Post-Doctoral Fellow

Job description:

  • Work with leading experts in the field of MRI and neuroimaging
  • Design and conduct research in the field of brain imaging
  • Help with image reconstruction and post-processing
  • Develop new ideas that promote current research
  • Support the preparation of project proposals and grant applications
  • Prepare and publish scientific manuscripts under the direction of CEO
  • Design, conduct, and evaluate experiments
  • Travel to Boston as needed

Minimum qualifications: A doctoral degree or equivalent in one of the following majors: Physics/ Medical Physics, Biomedical Engineering, Computer Science and Engineering, or Applied Mathematics. Doctoral candidates are also welcomed to apply. Excellent scientific writing ability and strong oral communication skills. The ability to work effectively and collegially in a multidisciplinary team.


Required: A strong background in at least one of the following areas: Biomedical Engineering, Biomedical Informatics, Biostatistics, Computer Science, Electrical and Computer Engineering, Signal Processing, Mathematics, or a related field. Strong programming skills in Python, MATLAB, C++ and modern machine learning platforms. A strong sense of responsibility to complete research in a timely manner. Candidates for postdoctoral positions are expected to work proactively, participate in research discussions, publish scholarly research papers, and disseminate research results.


Salary: $70,000 - $90,000 annually. The salary will be commensurate with experience.


The position will be for one year in the first instance but with a strong likelihood of continuing for several years, with career progression.


Location:  Orlando, FL.



Please send a resume and cover letter to info@imaginostics.com for consideration. No phone calls please. 

Grant Writer (full- or part-time)

Job description:

  • You will be responsible for drafting grant proposals for the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) Program, including grants for small feasibility studies
  • Identify grant proposal calls and collect the information in a shared document
  • Perform medical research, read state-of-the-art publications, and propose applications of our technology to the grants call
  • Draft grants for cancer research, traumatic brain injury, kidney disease, and additional diseases.
  • Identify and draft grants for the Autism Spectrum Disorder
  • Support CEO and other executives with writing of scientific materials, such as scientific conference abstracts and scholarly publications, as needed

Minimum qualifications: Bachelor’s degree. Excellent organizational skills, being able to work well independently and collaboratively. Excellent scientific writing ability and strong oral communication skills. Attention to details.


Preferred qualifications: Master’s degree in Sciences, Neurosciences, or related fields.


Salary range: $70,000 - $90,000 annually. The salary will be commensurate with experience.


Location: Orlando, FL.


Please send a resume and cover letter to info@imaginostics.com for consideration. No phone calls please.

Data-science Intern

Job description:

  • Work with leading experts in the field of MRI and neuroimaging
  • Analyze pre-clinical and/or clinical imaging data set
  • Prepare and publish scientific manuscripts

Minimum qualifications: A Bachelors or master’s Student from the following majors: Physics/ Medical Physics, Biomedical Engineering, Computer Science and Engineering, or Applied Mathematics. Excellent scientific writing ability and strong oral communication skills. The ability to work effectively and collegially in a multidisciplinary team.


Required: A strong interest in medical imaging and neuroscience. Candidates will be reviewed on a rolling basis.

This position is for a student intern. Remuneration considered on a case-by-case basis.


Location: Orlando, FL.


Please send a resume and cover letter to info@imaginostics.com for consideration. No phone calls please. 

Marketing and Communication Intern

Job description:

  • Prepare PowerPoint presentations about the Company and services for pharmaceutical companies.
  • Prepare market research reports and identify potential customers
  • Update the website and social media profiles with new information
  • Draft press releases and outreach to the press/ media for publication
  • Identify and draft applications to startup competitions in the fields of health tech, health care, neuro tech, longevity, and deep tech.
  • Draft quarterly updates to investors containing Company’s confidential information
  • Draft MailChimp’s emails for news updates to the public
  • Support Imaginostics’ staff on marketing or communications

Minimum qualifications: working towards a degree in communications, marketing, or related fields. Excellent written and oral communications skills. Must be independent and well organized, with an attention to details.


Required: A strong interest in medical imaging and neuroscience. Candidates will be reviewed on a rolling basis.

This position is for a student intern. Remuneration considered on a case-by-case basis.


Location: Orlando, FL.


Please send a resume and cover letter to info@imaginostics.com for consideration. No phone calls please.

Imaginostics, inc. is an Affirmative Action/Equal Opportunity Employer. We provide equal employment opportunities to all employees and applicants for employment and prohibits discrimination and harassment of any type without regard to race, color, religion, age, sex, national origin, disability status, genetics, protected veteran status, sexual orientation, gender identity or expression, or any other characteristic protected by Federal, State or local laws. This policy applies to all terms and conditions of employment, including recruiting, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation and training.

Imaginostics Awarded $915k NIH-NIA SBIR Grant for Clinical Validation its Novel MRI biomarkers in Screening and Quantification of Dementia

Imaginostics received a notice of award on September 15th, 2022, under the Small Business Innovation Research (SBIR) program to support a Phase I study entitled, “Validation of a Novel Magnetic Resonance Imaging (MRI) Technology for both Diagnostic Screening and Quantification of Brain Vascular Physiology in Alzheimer’s-Disease-Related Dementias.” Imaginostics is thrilled to be starting a pivotal clinical study at Brigham and Women’s Hospital (BWH) this Fall. The 96-subject study will test the ability to detect dementia early in patients with Mild Cognitive Impairment (MCI). A second arm of the study will test the ability to characterize an individual’s patients with Vascular Dementia (VaD). 

About Imaginostics:

Imaginostics, Inc., is a Boston-based longevity startup developing breakthrough magnetic resonance imaging (MRI) technology for precision medicine. It strives to create innovative, non-invasive diagnostic solutions using quantitative imaging biomarkers to provide new insight in health and disease. Its proprietary QUTE-CE (pronounced “cute-see”) MRI methodology can non-invasively assay vascular structure, function, and leakage in high resolution anywhere in the body, providing clinicians and scientists new endpoints for early detection and enhanced characterization of complex diseases. For more information on Imaginostics, Inc., please visit: www.imaginostics.com

Research reported in this publication was supported by the National Institute On Aging of the National Institutes of Health under Award Number R43AG079732. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Imaginostics Receives $725k Investment from the Alzheimer’s Drug Discovery Foundation (ADDF) for Clinical Validation of its Biomarkers in Alzheimer’s Disease and Related Dementias

On September 6th, 2022, Imaginostics received a $725,000 investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to support its pilot clinical study testing a novel imaging approach that can measure structure and function of the vascular system in the brain.

A significant portion of dementia cases have some aspect of cerebral small vessel disease, but current methods for quantitatively measuring vascular structure and function in living patients are limited. In their study, Imaginostics will collaborate with researchers at Harvard Medical School’s Brigham and Women’s Hospital to use their novel approach in patients with vascular dementia and mild cognitive impairment. If successful, Imaginostics would have a sensitive biomarker that could allow for earlier and more accurate diagnosis, as well as better clinical trial enrollment and outcome measurements of vascular function.

 

About Imaginostics:

Imaginostics, Inc., is a longevity startup developing breakthrough magnetic resonance imaging (MRI) technology for precision medicine. It strives to create innovative, non-invasive diagnostic solutions using quantitative imaging biomarkers to provide new insight in health and disease. Its proprietary QUTE-CE (pronounced “cute-see”) MRI methodology can non-invasively assay vascular structure, function, and leakage in high resolution anywhere in the body, providing clinicians and scientists new endpoints for early detection and enhanced characterization of complex diseases. For more information on Imaginostics, Inc., please visit: www.imaginostics.com

This content is solely the responsibility of the author and does not necessarily represent the official views of the Alzheimer’s Drug Discovery Foundation.

Privacy Policy

imaginostics

Tackling unmet clinical needs in non-invasive quantitative diagnostics

Privacy Policy

Last Modified: May 9th, 2022


Introduction
Imaginostics, Inc. (“We”, “Us”) respect your privacy and are committed to protecting it through our compliance with this policy.


This policy describes the types of information we may collect from you or that you may provide when you visit the website www.imaginostics.com (our “Website”), and our practices for collecting, using, maintaining, protecting, and disclosing that information. Please read the following carefully to understand our views and practices regarding your personal data and how we will treat it.

 
This policy applies to information we collect:

  • On this Website.
  • In email, text, and other electronic messages between you and this Website.
  • When you interact with our advertising and applications on third-party websites and services.

It does not apply to information collected by:

  • Us offline or through any other means, including on any other website operated by us or any third party; or
  • Any third party, including through any application or content that may link to or be accessible from or through the Website.

If you do not agree with our policies and practices, do not use our Website. By accessing or using this Website, you agree to this privacy policy.


Children Under the Age of 13

Our Website is not intended for children under 13 years of age. No one under age 13 may provide any information to the Website. We do not knowingly collect personal information from children under 13. If you are under 13, do not use or provide any information on this Website or register on the Website, make any purchases through the Website, use any of the interactive or public comment features of this Website or provide any information about yourself to us, including your name, address, telephone number, email address, or any screen name or user name you may use. If we learn we have collected or received personal information from a child under 13 without verification of parental consent, we will delete that information. If you believe we might have any information from or about a child under 13, please contact us immediately at the contact information provided at the bottom of this page.


Changes to Our Privacy Policy

This policy may be updated from time to time. If we make material changes to how we treat your personal information, we will notify you by updating the terms on our Website. The date the privacy policy was last revised is identified at the top of the page. You are responsible for periodically visiting our Website and this privacy policy to check for any changes, as your continued use of this Website after we make changes is deemed to be acceptance of those changes.


Information We Collect About You and How We Collect It
We may collect several types of information from and about users of our Website, including information:

  • Directly from you when you provide it to us; or
  • Automatically as you navigate through the site. Information collected automatically may include usage details, IP addresses, web browser used, and information collected through cookies and tracking technologies; or
  • From third parties, for example, our business partners


Information You Provide to Us
The information we collect on or through our Website may include:

  • Information that you provide by filling in forms on our Website. This includes information provided at the time of registering to use our Website or contacting us with questions or comments. We may also ask you for information when you report a problem with our Website;
  • Records and copies of your correspondence (including email addresses) if you contact us;
  • Your responses to surveys that we might ask you to complete for research purposes; or
  • Your search queries on the Website.


Information We Collect Through Automatic Data Collection Technologies
As you navigate through and interact with our Website, we may use automatic data collection technologies to collect certain information about your equipment, browsing actions, and patterns, including:

  • Details of your visits to our Website, including traffic data, location data, logs, and other communication data and the resources that you access and use on the Website.
  • Information about your computer and internet connection, including your IP address, operating system, and browser type.

We may also use these technologies to collect information about your online activities over time and across third-party websites or other online services (behavioral tracking).


The information we collect automatically is statistical data and may include personal information, but we may maintain it or associate it with personal information we collect in other ways or receive from third parties. It helps us to improve our Website and to deliver a better and more personalized service, including by enabling us to:

  • Estimate our audience size and usage patterns;
  • Store information about your preferences, allowing us to customize our Website according to your individual interests;
  • Speed up your searches; and
  • Recognize you when you return to our Website.


The technologies we use for this automatic data collection may include:

  • Cookies (or browser cookies). A cookie is a small file placed on the hard drive of your computer. You may refuse to accept browser cookies by activating the appropriate setting on your browser. However, if you select this setting you may be unable to access certain parts of our Website. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies when you direct your browser to our Website.
  • Flash Cookies. Certain features of our Website may use local stored objects (or Flash cookies) to collect and store information about your preferences and navigation to, from, and on our Website. Flash cookies are not managed by the same browser settings as are used for browser cookies.
  • Web Beacons. Pages of our Website and our emails may contain small electronic files known as web beacons (also referred to as clear gifs, pixel tags, and single-pixel gifs) that permit the Company, for example, to count users who have visited those pages or opened an email and for other related website statistics (for example, recording the popularity of certain website content and verifying system and server integrity).


How We Use Your Information
We use information that we collect about you or that you provide to us, including any personal information:

  • To present our Website and its contents to you;
  • To provide you with updates on information you request from us;
  • To gauge interest in web pages or topics featured on our Website;
  • To notify you about changes to our Website or any products or services we offer or provide though it;
  • To diagnose technical issues encountered during the use of our Website;
  • To comply with any legal obligations;
  • For fulfill any other purpose with your consent.


Disclosure of Your Information

We may disclose aggregated (non-personal) information about our users without restriction.
We may disclose personal information that we collect or you provide as described in this privacy policy:

  • To fulfill the purpose for which you provide it;
  • For any other purpose disclosed by us when you provide the information;
  • With your consent;
  • To comply with any court order, law, or legal process, including to respond to any government or regulatory request;
  • To enforce or apply our Terms of Use and other agreements; or
  • If we believe disclosure is necessary or appropriate to protect the rights, property, or safety of Imaginostics, Inc., our customers, or others.

Data Security

We have implemented measures designed to secure your personal information from accidental loss and from unauthorized access, use, alteration, and disclosure. However, the transmission of information via the internet is not completely secure. Although we do our best to protect your personal information, we cannot guarantee the security of your personal information transmitted to our Website. Any transmission of personal information is at your own risk. We are not responsible for circumvention of any privacy settings or security measures contained on the Website.


International Data Transfer

If you are a resident of a jurisdiction other than the United States, your personal information may be transferred, processed, or stored in another jurisdiction other than your home country, and may be subject to different data privacy laws and protections than those in the country of your residence. Please see Terms of Use for additional information.


State Privacy Rights

If you are a California, Nevada, Colorado, Virginia, or Utah resident, your state's laws may provide you with additional rights regarding our use of your personal information. If you are a resident of one of these states, please visit your state government’s website for more information.


Changes to Our Privacy Policy
It is our policy to post any changes we make to our privacy policy on this page. If we make material changes to these terms, we will give you notice by posting the latest terms on our Website. The date the privacy policy was last revised is identified at the top of the page. You understand and agree to periodically visit our Website and this privacy policy to check for any changes. Moreover, you are also responsible for ensuring we have an up-to-date active and deliverable email address for you in case we need to send any special or additional notice through email.


Contact Information
For questions or concerns about this privacy policy and our privacy practices, contact us at: website@imaginostics.com. 


  • by Codi
  • |
  • May 9, 2022

Disclaimers

imaginostics

Tackling unmet clinical needs in non-invasive quantitative diagnostics

legal disclaimers

Information for Consumers.
While the potential behind Imaginostics’ work is exciting, Imaginostics’ technology, solutions, and services are currently for research purposes and are used under the applicable institutional oversight of applicable collaboration partners. At this time, statements on this website and other information authored by Imaginostics (1) have not been evaluated by the U.S. Food and Drug Administration (FDA) and (2) are not intended to diagnose, treat, cure, or prevent any disease. If you are interested in any clinical research trials listed on this website, please speak to your physician to learn more. You can also find additional information on certain clinical trials at: www.clinicaltrials.gov.

Forward-Looking Statements.
Some of the information presented on this Website or presented in other materials authored by Imaginostics may constitute forward-looking information within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. These statements relate to future events or future predictions, including events or predictions relating to Imaginostics’ future financial performance, and are generally identifiable by the use of forward-looking terminology such as “believes”, “expects”, “may”, “will”, “should”, “plan”, “intend”, or “anticipates” or the negative thereof or other variations thereon or comparable terminology, or by discussion of strategy that involve risks uncertainties.

Imaginostics wishes to caution that these forward-looking statements and other statements contained herein are not historical facts but rather predictions and estimates regarding future events and circumstances that involve known and unknown risks, uncertainties and other factors. Such statements are based on assumptions that may not prove correct. Due to these risks and uncertainties, Imaginostics does not assure that any forward-looking statement will in fact transpire.

Statements Regarding NIH-Funded Research.
Content authored by Imaginostics appearing on this Website or on outside websites (e.g., our social media pages or posts) regarding research conducted under one or more National Institute of Health (NIH) grant(s), are solely the responsibility of the author, and do not necessarily reflect official views of the NIH.

  • by Codi
  • |
  • May 9, 2022

Website Terms

imaginostics

Tackling unmet clinical needs in non-invasive quantitative diagnostics

WEBSITE TERMS OF USE

Last Modified: May 9th, 2022

Acceptance of the Terms of Use

These terms of use, including the Privacy Policy and Legal Disclaimers, are entered into by and between you and Imaginostics, Inc. (“Company”, “we” or “us”), which shall be collectively referred to hereinafter as the “Terms of Use.” These Terms of Use govern your access to and use of www.imaginostics.com (the “Website”) and its content.


By using this Website, you represent and warrant that you have the legal capacity to form a binding contract between either you or any entity represented by you and the Company. If you do not possess the authority to so bind, you may not use the Website.


Changes to the Terms of Use

We may revise these Terms of Use at our sole discretion. All changes are effective upon publication. Your continued use thereafter indicates your acceptance to be bound by the changes. It is your responsibility to check this page from time to time when you access this Website so you are aware of any changes.


Reliance on Information Posted
The information presented on or through the Website is made available solely for general information purposes. We do not warrant the accuracy or completeness of this information or that its up-to-date. Any reliance you place on such information is strictly at your own risk. We disclaim all liability and responsibility arising from any reliance placed on such materials by you.

Without limiting the above, the Company hereby informs you that NOTHING ON THIS WEBSITE IS INTENDED AS LEGAL, FINANCIAL, MEDICAL OR PROFESSIONAL ADVICE; the Company specifically disclaims responsibility for your reliance on any information presented on this Website as legal, financial, medical or professional advice. Please refer to our Legal Disclaimers for further discussion.

Intellectual Property Rights
This Website, including its content and functionality, are owned by the Company or third-party rights holders from which the Company has a license to use. Such content and functionality are protected by United States and international copyright, trademark, patent, trade secret and other intellectual property or proprietary rights laws. You may not reproduce, distribute, modify, create derivative works of, publicly display, republish, or use any of the material on this Website for a commercial purpose.
The Company name, “Imaginostics,” logos, designs and slogans are trademarks of the Company. You may not use such marks without the prior written permission of the Company. All other names, logos, designs and slogans on this Platform are the trademarks of their respective owners.


Prohibited Uses
You may use this Website only for lawful purposes and in accordance with these Terms of Use.
You agree not to use the Website:

  • In any way that violates any applicable federal, state, local or international law or regulation (including, without limitation, any laws regarding the export of data or software to and from the US or other countries).
  • To transmit, or procure the sending of, any advertising or promotional material, including any “junk mail”, “chain letter” or “spam” or any other similar solicitation.
  • To impersonate or attempt to impersonate the Company, a Company employee, another user or any other person or entity (including, without limitation, by using e-mail addresses associated with any of the foregoing).
  • To engage in any other conduct that restricts or inhibits anyone’s use or enjoyment of the Website, or which, as determined by us, may harm the Company or users of the Website or expose them to liability.


Links from the Website

Links provided on this Website to other sites or third-party resources are for your convenience. We have no control over the contents of those sites or resources, and accept no responsibility for them or for any loss or damage that may arise from your use of them. If you decide to access any of the third-party websites linked to this website, you do so entirely at your own risk and subject to the terms and conditions of use for such websites.


Information Gathered from You
Please refer to the Privacy Policy.

Geographic Restrictions
The owner of the Platform is based in the state of Delaware in the United States. We provide this Platform for use only by persons located in the United States. We make no claims that the Platform or any of its content is accessible or appropriate outside of the United States. Access to the Platform may not be legal by certain persons or in certain countries. If you access the Platform from outside the United States, you do so on your own initiative and are responsible for compliance with local laws.


Disclaimer of Warranties
You understand that we cannot and do not guarantee or warrant that files available for downloading from the internet or the Website will be free of viruses or other destructive code. You are responsible for implementing sufficient procedures and checkpoints to satisfy your particular requirements for anti-virus protection and accuracy of data input and output, and for maintaining a means external to our site for any reconstruction of any lost data. TO THE FULLEST EXTENT PROVIDED BY LAW, WE WILL NOT BE LIABLE FOR ANY LOSS OR DAMAGE CAUSED BY A DISTRIBUTED DENIAL-OF-SERVICE ATTACK, VIRUSES, OR OTHER TECHNOLOGICALLY HARMFUL MATERIAL THAT MAY INFECT YOUR COMPUTER EQUIPMENT, COMPUTER PROGRAMS, DATA, OR OTHER PROPRIETARY MATERIAL DUE TO YOUR USE OF THE WEBSITE OR ANY SERVICES OR ITEMS OBTAINED THROUGH THE WEBSITE OR TO YOUR DOWNLOADING OF ANY MATERIAL POSTED ON IT, OR ON ANY WEBSITE LINKED TO IT.


YOUR USE OF THE WEBSITE, ITS CONTENT, AND ANY SERVICES OR ITEMS OBTAINED THROUGH THE WEBSITE IS AT YOUR OWN RISK. THE WEBSITE, ITS CONTENT, AND ANY SERVICES OR ITEMS OBTAINED THROUGH THE WEBSITE ARE PROVIDED ON AN "AS IS" AND "AS AVAILABLE" BASIS, WITHOUT ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. NEITHER THE COMPANY NOR ANY PERSON ASSOCIATED WITH THE COMPANY MAKES ANY WARRANTY OR REPRESENTATION WITH RESPECT TO THE COMPLETENESS, SECURITY, RELIABILITY, QUALITY, ACCURACY, OR AVAILABILITY OF THE WEBSITE. WITHOUT LIMITING THE FOREGOING, NEITHER THE COMPANY NOR ANYONE ASSOCIATED WITH THE COMPANY REPRESENTS OR WARRANTS THAT THE WEBSITE, ITS CONTENT, OR ANY SERVICES OR ITEMS OBTAINED THROUGH THE WEBSITE WILL BE ACCURATE, RELIABLE, ERROR-FREE, OR UNINTERRUPTED, THAT DEFECTS WILL BE CORRECTED, THAT OUR SITE OR THE SERVER THAT MAKES IT AVAILABLE ARE FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS, OR THAT THE WEBSITE OR ANY SERVICES OR ITEMS OBTAINED THROUGH THE WEBSITE WILL OTHERWISE MEET YOUR NEEDS OR EXPECTATIONS.


TO THE FULLEST EXTENT PROVIDED BY LAW, THE COMPANY HEREBY DISCLAIMS ALL WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, STATUTORY, OR OTHERWISE, INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT, AND FITNESS FOR PARTICULAR PURPOSE.
THE FOREGOING DOES NOT AFFECT ANY WARRANTIES THAT CANNOT BE EXCLUDED OR LIMITED UNDER APPLICABLE LAW.


Governing Law and Jurisdiction
All matters relating to the these Terms of Use and any dispute or claim arising therefrom or related thereto (in each case, including non-contractual disputes or claims), shall be governed by and construed in accordance with the internal laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction).


Any legal suit, action or proceeding arising out of, or related to, these Terms of Use shall be instituted exclusively in the federal courts of the United States or the courts of the Commonwealth of Massachusetts although we retain the right to bring any suit, action or proceeding against you for breach of these Terms of Use in your country of residence or any other relevant country; you waive any and all objections to the exercise of jurisdiction over you by such courts and to venue in such courts.


Waiver and Severability

No waiver of by the Company of any term or condition set forth in these Terms of Use shall be deemed a further or continuing waiver of such term or condition or a waiver of any other term or condition, and any failure of the Company to assert a right or provision under these Terms of Use shall not constitute a waiver of such right or provision.


If any provision of these Terms of Use is held by a court or other tribunal of competent jurisdiction to be invalid, illegal or unenforceable for any reason, such provision shall be eliminated or limited to the minimum extent such that the remaining provisions of the Terms of Use will continue in full force and effect.

 
Entire Agreement
The Terms of Use and Privacy Policy constitute the sole and entire agreement between you and Imaginostics, Inc. with respect to the Website and supersede all prior and contemporaneous understandings, agreements, representations and warranties, both written and oral, with respect to the Website.

  • by Codi
  • |
  • May 9, 2022

Imaginostics Awarded SBIR Grant from NIH for Translating QUTE-CE MRI Technology for Pre-Clinical Drug Development and Research Applications

The National Institute of Mental Health (NIMH) issued a notice of award on January 11, 2022, to Imaginostics, Inc., under the Small Business Innovation Research (SBIR) program to support a Phase I study entitled, “Development of a Frontier Magnetic Resonance (MR) Imaging Technology As a Tool for Visualization and Quantified Vascular-Feature Measurement for Use in Brain and Behavioral Research on Small Animals.” The research project aims to develop and optimize a software prototype implementing Imaginostics’ imaging technology for use with industry-standard small animal research scanners followed by testing and analytical characterization of biomarkers.

Imaginostics has brought together world-leading experts from academia and industry to accelerate drug development and understanding of the brain and mental illness by providing meaningful endpoints.

The research project reported here is supported by the National Institute of Mental Health of the National Institutes of Health under award number R43MH129045. The amount of federal funding for this project totals $436,556.

About Imaginostics:

Imaginostics, Inc., is a Boston-based health tech startup developing breakthrough magnetic resonance imaging (MRI) technology for precision medicine. It strives to create innovative, non-invasive diagnostic solutions using quantitative imaging biomarkers to provide new insight in health and disease. Its proprietary QUTE-CE (pronounced “cute-see”) MRI methodology can non-invasively assay vascular structure, function, and leakage in high resolution anywhere in the body, providing clinicians and scientists new endpoints for early detection and enhanced characterization of complex diseases. For more information on Imaginostics, Inc., please visit: www.imaginostics.com

This content is solely the responsibility of the author and does not necessarily represent the official views of the National Institutes of Health.

1 2 3